Crossed chemoprophylaxis assay between adriamycin and cis-platinum in recurrent superficial bladder tumor

Of 146 patients with superficial bladder carcinoma, 66 (35 primary and 31 recurrent from failure of thiotepa chemoprophylaxis) relapsed following transurethral resection (TUR) and chemotherapy with adriamycin or cis-platinum. A new TUR was carried out. In case of progression in the number of tumors, size, stage or grade, treatment was begun with the other drug. If the tumor had the same characteristics, treatment was continued with the same drug. In both the primary and recurrent tumors with or without progression, cis-platinum controlled the tumor better than adriamycin, rescuing it from the latter and obtaining a recurrence index and disease-free interval as with cis-platinum alone. These results are more conclusive in primary tumors.

Thiotepa versus adriamycin versus cis-platinum in the intravesical prophylaxis of superficial bladder tumors

A study was performed on 184 patients with superficial bladder cancer (pTa, pT1), 92 with primary and 92 recurrent tumors. After TUR of all visible lesions, endovesical chemotherapy with thiotepa, adriamycin or cis-platinum was started on the 15th and 30th days following surgery. There were no statistically significant differences between any of the three chemotherapies at the doses and intervals mentioned. Only cis-platinum has proven to be more effective in primary high grade tumor.

Urinary lipids in vesical carcinoma: a new biological marker. Preliminary study

We have determined urinary lipids by thin-layer chromatography in 40 patients with bladder tumors, and have evaluated their modification following tumor removal and their predictive value in terms of the presence or absence of recurrences. The results obtained were compared with those of a control group without tumoral pathology (14 patients) and 11 cases with bacterial infection of the urinary tract. There is a marked difference between the lipidogram of the tumoral group of patients and the controls (p less than 0.005), especially in the phospholipid to fatty acid (PL/FA) relationship, with a specificity of 100% and a sensitivity of 80%. With regard to recurrences, in non-recurrent cases the PL/FA value remained high in relation to the initial value (p less than 0.005), whereas in the recurrent cases the value rose to 'tumoral limits'. Macrohematuria and urinary infection modify the lipidogram, resulting in values similar to the tumoral cases. Their absence is therefore essential in order to evaluate the results. The urinary lipidogram appears to be a possible biological marker for bladder tumors.